Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report
Malignant eccrine porocarcinoma is a very rare tumor and the etiology is not known. Treatment is surgical removal of the tumor. The benefit of chemotherapy and radiotherapy is unclear. A 49-year-old male patient presented with the complaint of left inguinal swelling. Ultrasonography examination revealed 5x4 cm inguinal lymphadenopathy. The inguinal lymph nodes were excised. Pathology report indicated eccrine porocarcinoma. The patient was treated with cisplatin 40 mg/m2 week as well as concurrent radiotherapy for 5 weeks. After 6 weeks of dual therapy, liver metastases were detected. KRAS, NRAS, and BRAF tests were negative. Gemcitabine was administered at a dose of 1000 mg/m2 on days 1 and 8 every 21 days, and docetaxel was administered at a dose of 75 mg/m2 on day 8, every 21 days. There was progression after 2 cycles of chemotherapy. The patient lived 7 months. In this case, use of synchronous cisplatin and radiotherapy as adjuvant treatment could not prevent tumor metastasis. The combination chemotherapy of docetaxel and gemcitabine applied after metastatic disease development was ineffective.
1.Sean RC, David JL. Cancer of the Skin. In: Devita VT, Hellman S and Rosenberg SA editors. Cancer: Principles and practice of oncology. 10th ed. Philadelphia, Pennsylvania: Lippincott-Raven;2015: p. 1332–4.
2. Cazeau C, Lepreux S, Taieb A, Delaunay M, Jouary T. Eccrine porocarcinoma: a highly malignant tumor with a poor prognosis. Ann Dermatol Venereol 2008;135:722–4. [CrossRef]
3. Arbona E, Balme B. Eccrine poroma and porocarcinoma. Ann Dermatol Venereol 2010;137:660–2. [CrossRef]
4. Pinkus H, Mehregan AH. Epidermotropic eccrine carcinoma. A case combining features of eccrine poroma and Paget’s dermatosis. Arch Dermatol 1963;88:597–606. [CrossRef]
5. Wick MR, Goellner JR, Wolfe JT 3rd, Su WP. Adnexal carcinomas of the skin. I. Eccrine carcinomas. Cancer 1985;56:1147–62.
6. Huet P, Dandurand M, Pignodel C, Guillot B. Metastasizing eccrine porocarcinoma: report of a case and review of the literature. J Am Acad Dermatol 1996;35:860–4. [CrossRef]
7. Pernia LR, Guzman-Stein G, Miller HL. Surgical treatment of an aggressive metastasized eccrine poroma. Ann Plast Surg 1993;30:257–9. [CrossRef]
8. Marone U, Caracò C, Anniciello AM, Di Monta G, Chiofalo MG, Di Cecilia ML, et al. Metastatic eccrine porocarcinoma: report of a case and review of the literature. World J Surg Oncol 2011;9:32. [CrossRef]
9. Plunkett TA, Hanby AM, Miles DW, Rubens RD. Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. Ann Oncol 2001;12:411–4. [CrossRef]
10. Morris DM, Sanusi ID, Lanehart WH. Carcinoma of eccrine sweat gland: experience with chemotherapy, autopsy findings in a patient with metastatic eccrine carcinoma, and a review of the literature. J Surg Oncol 1986;31:26–30. [CrossRef]
11. Aaribi I, Mohtaram A, Ben Ameur El Youbi M, Kharmoum J, El Kabous M, Mrabti H, et al. Successful management of metastatic eccrine porocarcinoma. Case Rep Oncol Med 2013;2013:282536. [CrossRef]
12. Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol 2001;25:710– 20. [CrossRef]